News & Updates

Results from the Italian RISP* trial presented at WCLC 2026 show improvement in smoking cessation rates following treatment with cytisine, a partial agonist of α4β2nicotinic acetylcholine receptors.

Arginine therapy is no better than placebo in terms of improving outcomes in children and young adults with sickle cell disease (SCD) who are experiencing acute pain episodes, according to the phase III STArT trial.

In the first-line treatment of patients with advanced HER2-mutant non-small cell lung cancer (NSCLC), trastuzumab deruxtecan (T-DXd) monotherapy confers a 6-month improvement in progression-free survival (PFS) compared with pembrolizumab plus chemotherapy, as shown in the phase III DESTINY-Lung04 trial.

Among people living with HIV who are initiating antiretroviral therapy (ART), those with obesity potentially face a higher long-term risk of cardiovascular disease (CVD), cancer, or death, according to an observational study.

Measurements of rituximab serum concentration are predictive of future drug concentrations associated with early B-cell repopulation in children with inflammatory diseases, suggests a study.

A 5-year analysis of the phase III ALLEGRO-LT study, presented at EADV 2026, shows that patients with the least baseline scalp hair loss respond best and fastest to the Janus kinase (JAK) inhibitor ritlecitinib.

New drug applications approved by US FDA as of 16-30 September 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.